37 "Breast" clinical trials found.
-
A Phase 1b/2 Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
This is a multicenter, Phase 1b/2 trial. The Phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in ...Phase
Interventional
-
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1 ER Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)
This study wants to see if giving extra chemotherapy (adjuvant chemotherapy (ACT) to ovarian function suppression plus endocrine therapy) helps premenopausal women with early-stage breast ...
Phase
Interventional
-
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
OptimICE-pCR is a randomized phase III trial that is enrolling early-stage TNBC patients with a pCR after the completion of neoadjuvant therapy consisting of a ...Phase
Interventional
-
Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi- institutional study
Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi- institutional studyPhase
Interventional
-
A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients with Triple Negative Breast Cancer That Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
This is an international, multicenter, open-label, randomized, Phase 3 study in patients with TNBC who have received neoadjuvant chemotherapy with or without checkpoint inhibitor (CPI ...Phase
Interventional
-
I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
The I-SPY 2.2 protocol uses the same strategy as the I-SPY 2.0 protocol to optimize response, measuring the impact of each therapeutic regimen ...Phase
Interventional
-
A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Primary Objective: To estimate subsequent recurrence-free survival (RFS) at 3 years for ribociclib when administered with ET (AIs or fulvestrant), in patients with Hormone Receptor ...Phase
Interventional
-
A Phase 1 First-in-Human Study of MEN2312 a KAT6 Inhibitor as Monotherapy and in Combination in Participants With Advanced Breast Cancer
This is the first study in people to test a new drug called MEN2312 (an experimental cancer drug) for the treatment of advanced breast cancer ...
Phase
Interventional
-
S2206 Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
This is a randomized Phase III trial. Eligible participants either are known to have ultrahigh risk (MP2) status using MammaPrint or will undergo screening to ...Phase
Interventional
-
A Phase 1 First in human Dose Escalation and Expansion Multicenter Study of XMT-1660 in Participants with Solid Tumors
The proposed first-in-human study of XMT-1660 will be a Phase 1, open-label trial of XMT-1660 in previously treated participants with metastatic TNBC, HR+/HER2- or ...Phase
Interventional
